Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets
BMO Capital Markets has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating, contributing to a consensus "buy" rating among analysts with a target price of $7.69. The company's shares opened at $3.54, with a market capitalization of $642 million, after reporting a quarterly loss in line with estimates but revenue below expectations. Institutional investors hold a significant 70.37% of the company's stock.
BMO initiates Prime Medicine stock with outperform rating
BMO Capital has initiated coverage on Prime Medicine (NASDAQ:PRME) with an outperform rating and a $9.00 price target, representing a nearly 3x upside. The firm highlighted Prime Editing as a differentiated gene-editing platform and noted that Prime Medicine's lead programs, PM577 and PM647, are advancing toward clinical readouts in 2027. This follows a favorable arbitration outcome with Beam Therapeutics and positive reiterations from other analysts, underscoring the company's progress in its therapeutic projects despite burning cash.
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside
The average 12-month price target for Prime Medicine, Inc. (PRME) stock has been lowered from $7.12 to $6.92 by 9 analysts, yet this new target still suggests a significant 124% potential upside from its August 14th closing price. The consensus rating for PRME remains a "Buy" among 12 analysts, with 9 recommending a Buy and 3 a Hold.
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright
HC Wainwright has revised its Q3 2026 EPS estimate for Prime Medicine (NASDAQ: PRME) to a loss of $0.28 per share, a slight improvement from the previous forecast of $0.29. Despite maintaining a "Buy" rating and an $8.00 price target, analysts still anticipate the company will remain unprofitable until 2030. Prime Medicine recently reported a quarterly loss of $0.24 per share, meeting consensus, but its revenue of $1.15 million significantly missed analyst estimates of $4.40 million.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained its target price at $8. This indicates a continued positive outlook from the firm regarding Prime Medicine's stock performance.
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME
Renaissance Technologies LLC has reduced its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 35.5%, selling 408,120 shares but still retaining 741,039 shares valued at approximately $2.58 million. This comes as Prime Medicine reported a quarterly loss of $0.24 per share, meeting analyst estimates, yet its revenue of $1.15 million fell short of the $4.40 million forecast. Despite ongoing negative profitability, analysts maintain a "Moderate Buy" consensus with an average price target of $7.53, significantly above the current stock price of around $3.08.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced its financial results for the second quarter of 2026 and provided business updates, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing rights for PM647 in Alpha-1 Antitrypsin Deficiency, and was granted Regenerative Medicine Advanced Therapy (RMAT) designation for PM359. Prime Medicine reported a net loss of $42.1 million for the quarter and a cash position of $108.8 million, projecting a cash runway into 2027.
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating, while other analysts maintain a "Moderate Buy" consensus with an average price target of $7.53. The company's shares opened at $3.08, significantly below its 52-week high, and it met EPS expectations but fell short on revenue. Institutional investors hold a substantial stake in Prime Medicine, with some firms recently increasing their positions.
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24
Prime Medicine, Inc. reported its Q2 earnings per share (EPS) at USD -0.24. This brief update was sourced from Reuters and made available on TradingView.
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary
Prime Medicine, Inc. (PRME) reported its Q2 2026 financial results, showing revenue of $11.04 million and a net loss of ($42.11M), resulting in a diluted EPS of ($0.24). This represents a decrease in revenue but an improvement in net loss and EPS compared to the prior-year quarter. The company attributed growth to higher product sales, increased service uptake, and a strategic shift towards digital and direct-to-consumer channels.
Prime Medicine expects 2027 data from two liver gene therapies
Prime Medicine reported its second-quarter 2026 financial results, including a narrowed net loss of $42.1 million and cash reserves of $108.8 million, expected to fund operations into 2027. The company announced significant pipeline progress, with initial clinical data for its two liver gene therapies, PM577a (Wilson disease) and PM647 (Alpha-1 Antitrypsin Deficiency), anticipated in 2027. Additionally, PM359 received an FDA RMAT designation, supporting an expedited path toward a potential BLA submission in the first half of 2027.
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates
Prime Medicine (NASDAQ:PRME) announced its earnings results, reporting a quarterly loss of $0.24 per share, which matched analysts' consensus estimates. Despite this, the company continues to face deeply negative profitability metrics, including a net margin of -4,917.55%. Shares traded down to $2.95, near its 52-week low, while institutional investors hold a significant portion of its stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $7.53.
Prime Medicine, Inc. (PRME) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Prime Medicine, Inc. (PRME), including its current stock price, trading activity, historical data, and company overview. It highlights key financial metrics, recent news, performance comparisons against the S&P 500, and analyst ratings, alongside details of its therapeutic product pipeline and Prime Editing technology. The article also lists comparable biotechnology companies and general market data.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.24 per share, aligning with Zacks Consensus Estimate but missing revenue estimates significantly at $1.15 million. The company has consistently missed revenue expectations over the last four quarters, and its shares have underperformed the S&P 500 year-to-date. Despite the Q2 results, the stock currently holds a Zacks Rank #2 (Buy) due to favorable estimate revisions ahead of the report.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine has reported its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and an arbitration resolution affirmed its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with regulatory submission expected in Q3 2026. PM359 for chronic granulomatous disease also received Regenerative Medicine Advanced Therapy designation, moving towards a BLA submission in H1 2027, all while maintaining a cash runway into 2027.
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine has announced its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and anticipates initial clinical data in 2027. Additionally, Prime Medicine resolved an arbitration with Beam Therapeutics, affirming its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with regulatory submission expected in Q3 2026, and PM359 received Regenerative Medicine Advanced Therapy designation, moving towards a BLA submission in the first half of 2027.
PRME|Prime Medicine Inc|Price:2.935|Chg%:+0.125
This article provides a comprehensive stock analysis of Prime Medicine Inc (PRME) from TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry. The company, which specializes in gene editing therapies, has significant growth potential, high institutional ownership, and a strong "Buy" rating from analysts with a target price of $7.12. Despite recent weak stock market performance, its fundamentals are stable, and the stock is trading sideways, making it suitable for range-bound swing trading.
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages
Prime Medicine, Inc. (NASDAQ:PRME) has received an average "Moderate Buy" recommendation from eight brokerages, with six analysts rating it a buy, one a strong buy, and one a sell. The average 12-month price target is $7.53, significantly higher than its recent share price of $2.92. Despite missing quarterly earnings estimates with a loss of $0.28 per share on $0.86 million in revenue, institutional investors like State Street Corp and Balyasny Asset Management have recently increased their stakes in the company.
Prime Medicine(PRME) Stock Options Chain | Quotes & News
This article provides access to the stock options chain for Prime Medicine (PRME), including detailed quotes and relevant news. It serves as a resource for investors interested in the company's options trading data and market developments.
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) is expected to report a year-over-year increase in earnings and higher revenues for Q2 2026. However, Zacks' Earnings ESP model, which compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggests that analysts have recently become bearish, resulting in an Earnings ESP of -15.86%. Despite a Zacks Rank #2 (Buy), this combination makes it difficult to conclusively predict an earnings beat, especially given the company has only surpassed EPS estimates once in the last four quarters.
Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME
Redmile Group LLC has acquired a new position in Prime Medicine, Inc. (NASDAQ:PRME) worth approximately $5.54 million, making it their 28th largest holding. Other institutional investors have also adjusted their stakes in the gene editing company. Analysts currently have an average "Moderate Buy" rating for Prime Medicine with an average target price of $7.53, despite the company reporting a wider-than-expected loss in its last earnings call.
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME
ADAR1 Capital Management LLC has initiated a new position in Prime Medicine, Inc. (NASDAQ:PRME) by purchasing 1,973,282 shares valued at approximately $6.87 million during the first quarter. This investment makes ADAR1 Capital Management LLC the owner of about 1.09% of Prime Medicine. Several other institutional investors have also adjusted their holdings in the company, which currently holds a "Moderate Buy" rating from analysts with a consensus target price of $7.53.
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Prime Medicine Inc (PRME), noting that relevant data for business segments and profit contribution have not yet been disclosed by the company for FY2025 and FY2024. It highlights that the company reported $4.63 million in revenue from the United States, representing 0.00% of the total, indicating a lack of comprehensive disclosure for a full revenue picture.
Prime Medicine Market Sentiment
This article provides an overview of market sentiment for Prime Medicine (PRME), detailing analyst consensus, short interest, options flow, and recent analyst actions. Key signals show a "Buy" analyst consensus, 24.6% short float, and a 1.58 P/C ratio for options. The article also lists historical analyst ratings, price target changes, and actions from various firms for PRME.
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME
This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, indicating the company's stock market status and offering various analytical tools and data points.
Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $11
Oppenheimer has reiterated its Buy rating for Prime Medicine (PRME.US), maintaining a target price of $11. This indicates continued confidence in the company's prospects from the investment firm.
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History
This article provides a detailed financial overview of Prime Medicine, Inc. (PRME), including its current stock price, recent performance, key financial metrics, and company overview. It highlights the company's biotechnology focus on genetic medicines and its lead therapeutic product candidates, along with analyst insights and comparisons to similar biotechnology companies.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine, Inc. announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD). This clearance, along with a previously approved New Zealand Clinical Trial Application, establishes a global Phase 1/2 clinical program for PM577a in patients with H1069Q-mutated Wilson disease. The company expects to initiate the Phase 1/2 trial in the second half of 2026 with initial clinical data anticipated in 2027.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine has received U.S. FDA clearance for its Investigational New Drug (IND) application for PM577a, an in vivo Prime Editor for Wilson disease (WD). This clearance, combined with a previously approved New Zealand Clinical Trial Application, establishes a global Phase 1/2 clinical program. PM577a targets the H1069Q mutation, the most common WD-causing allele in North America and Europe, with initial clinical data expected in 2027.
Prime Medicine expects first-in-human Wilson trial in second half of 2026
Prime Medicine (Nasdaq: PRME) announced that the U.S. FDA cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease. This clearance, combined with a previously approved Clinical Trial Application in New Zealand, allows for a global Phase 1/2, first-in-human trial targeting the H1069Q mutation in the ATP7B gene. The trial is expected to begin in the second half of 2026, with initial clinical data anticipated in 2027.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM577a, an in vivo Prime Editor for Wilson disease. This clearance, following a New Zealand CTA, establishes a global Phase 1/2 clinical program, with initial data expected in 2027. PM577a targets the H1069Q mutation, the most common WD-causing allele in North America and Europe, offering a potential one-time curative therapy.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine, Inc. announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD). This clearance, combined with a previously cleared New Zealand Clinical Trial Application (CTA), establishes a global Phase 1/2 clinical program for PM577a, targeting the H1069Q mutation which is the most prevalent WD-causing allele in North America and Europe. The company expects to initiate the Phase 1/2 trial in the second half of 2026 and anticipate initial clinical data in 2027, aiming to provide a one-time curative genetic therapy for the serious, progressive disorder.
Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com
Prime Medicine Inc. announced that the FDA has cleared its Investigational New Drug application for PM577a, a gene editing treatment for Wilson disease. This clearance, combined with a previous approval in New Zealand, allows the company to proceed with a global Phase 1/2 clinical program. The therapy targets the H1069Q mutation and is expected to begin trials in the second half of 2026, with initial data anticipated in 2027.
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify
Cathie Wood's ARK Invest made significant portfolio adjustments on Monday, focusing on increasing holdings in gene editing, AI infrastructure, and space economy companies like Prime Medicine, Tempus AI, and SpaceX. Simultaneously, ARK reduced positions in certain biotech firms such as AtaiBeckley, e-commerce platform Shopify, and traditional tech stocks like Baidu, Robinhood, and AMD, indicating a strategic rebalancing towards disruptive innovation. These moves reflect a refined approach to portfolio management, prioritizing emerging technologies with high growth potential.
Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. reduced its stake in Prime Medicine (NASDAQ:PRME) by 9.4% in the first quarter, now holding 2.94 million shares valued at $10.23 million. Despite this reduction, institutional ownership remains high at 70.37%, with other major institutional investors like State Street Corp., Balyasny Asset Management, and UBS Group AG significantly increasing their positions. Analysts have a "Moderate Buy" consensus rating for Prime Medicine, with an average price target of $7.53, even though the company recently reported a wider-than-expected quarterly loss.
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ
The NASDAQ page for Prime Medicine Inc. (PRME) shows its stock price at $3.22, a decrease of $0.07 (-2.17%). Currently, there are no analyst ratings or earnings information available for PRME. The page also includes general disclaimers about the risks of stock trading and day trading profitability, provided by Millionaire Media, LLC.
Prime Medicine Stock Dips As Traders Weigh Heavy Losses
Prime Medicine Inc. (PRME) stock has dipped by 9.69% due to negative sentiment surrounding its latest pipeline developments and significant financial losses despite minimal revenue. The company is characterized as a high-risk, early-stage gene-editing platform with a limited cash runway. Analysts expect further downside given negative margins, potential future dilution, and strong technical resistance.
Prime Medicine Stock Dips As Traders Weigh Heavy Losses
Prime Medicine Inc. (NASDAQ: PRME) has seen its stock dip by 9.69% due to negative sentiment regarding its latest pipeline developments and significant financial losses. The company, an early-stage gene-editing platform, shows minimal revenue against high operating expenses and a leveraged balance sheet, making it a speculative vehicle for traders rather than an investment based on earnings strength. Technical analysis suggests a failed recent breakout and strong resistance levels, indicating a downside risk until clear clinical or partnership catalysts emerge.
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME
This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The article is primarily a data point page from TradingView, focusing on key financial metrics for the biotechnology company.
Prime Medicine gains after winning arbitration with Beam Therapeutics
Prime Medicine's stock rose in after-hours trading following a favorable decision in its arbitration with Beam Therapeutics. The arbitration ruling confirmed that Prime Medicine holds exclusive rights to certain foundational intellectual property for its PRIME editing technology.
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk
Prime Medicine (PRME) stock is experiencing a significant decline, currently down nearly 14%. This puts the company on track for its largest percentage decrease since May 2025. The article highlights this notable drop in stock performance for Prime Medicine.
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway
Prime Medicine Inc. (PRME) stock is down over 10% as traders react to its heavy losses and uncertain cash runway despite an earlier rally. While the company boasts high gross margins and some liquidity with $135.5M in cash, it faces significant quarterly net losses and R&D spending, making it a speculative trading vehicle driven by price action and catalysts. Traders are advised to focus on technical levels and disciplined risk management rather than long-term investment.
Prime Medicine Wins AATD Gene Therapy Arbitration
Prime Medicine has won an arbitration against Beam Therapeutics, confirming its exclusive development rights for PM647, a prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This decision clears PM647 for clinical entry, with an IND/CTA filing targeted for Q3 2026 and initial human data expected in 2027. The ruling is significant as it allows Prime Medicine to advance its program despite Beam having a competing, more clinically advanced AATD therapy.
Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute
Prime Medicine's shares saw a significant increase following an arbitration panel's ruling in its favor against Beam Therapeutics, upholding the validity of certain intellectual property licensed exclusively to Prime Medicine. The decision confirms the validity of foundational patents and claims related to Prime Editing technology, initially developed at the Broad Institute before being licensed to Beam and subsequently sublicensed to Prime Medicine. This ruling is expected to strengthen Prime Medicine's position in the gene editing space.
Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Prime Medicine, Inc. (NASDAQ:PRME) a consensus "Moderate Buy" rating, with an average 12-month price target of $7.53. The stock rose 15.8% recently, trading at $4.62, below its 52-week high of $6.94. The company reported a wider-than-expected quarterly loss of $0.28 per share on $0.86 million in revenue, with analysts projecting a full-year EPS of -0.98.
Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Prime Medicine has won an arbitration dispute against Beam Therapeutics regarding gene-editing technology for alpha-1 antitrypsin deficiency (AATD). The ruling allows Prime to proceed with clinical trials for AATD and is a setback for Beam, which called the decision disagreed with the ruling. Both companies were spun out of the same lab and had a 2019 agreement to prevent competition.
Prime Medicine stock surges after winning arbitration with Beam
Prime Medicine Inc. (NASDAQ: PRME) shares rose significantly after the company won a binding arbitration ruling against Beam Therapeutics Inc. (NASDAQ: BEAM). The ruling confirms Prime Medicine's development rights to PM647, an investigational treatment for Alpha-1 Antitrypsin Deficiency, and clarifies that Prime Medicine did not breach their agreement and owes no monetary damages. Prime Medicine now plans to move PM647 into clinical trials, with an investigational new drug application expected in Q3 2026 and initial clinical data in 2027.
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
Prime Medicine has won a patent dispute against Beam Therapeutics, allowing it to continue developing its lead gene-editing therapy, PM647, for alpha-1 antitrypsin deficiency (AATD). The arbitration tribunal ruled that Prime did not violate its 2019 agreement with Beam and does not owe any damages. This decision clears the way for Prime to advance PM647 into clinical trials, despite Beam's expressed disagreement and the indication that it considers the intellectual property struggle ongoing.
Prime Medicine resolves arbitration, clarifying PM647 development rights
Prime Medicine, Inc. announced that an arbitration tribunal ruled in its favor regarding its PM647 development candidate, affirming it falls within Prime's agreed field and dismissing Beam Therapeutics' claims. This resolution clarifies Prime Medicine's development rights and removes legal uncertainty, positively impacting the company and its stakeholders. Despite the positive legal outcome, TipRanks’ AI Analyst, Spark, rates PRME as Neutral due to weak financial performance and limited technical data.
Prime Medicine wins arbitration over AATD therapy PM647
Prime Medicine Inc. (NASDAQ:PRME) has won an arbitration against Beam Therapeutics Inc. concerning its investigational therapy PM647 for Alpha-1 Antitrypsin Deficiency, confirming the drug falls within Prime Medicine’s licensed field and no monetary damages are owed. This ruling removes a significant legal hurdle for PM647's clinical development, with Prime Medicine planning to submit an investigational new drug application in Q3 2026. Despite trading above its fair value, the company maintains strong liquidity and has seen a 15% year-to-date stock gain, further supported by recent positive analyst ratings and clinical trial clearances for another therapy, PM577a.
